Recent Pilot Studies Demonstrate Value Of Vaniqa To Women First HealthCare; Data Supports the Role of Vaniqa in Improving Laser Hair Removal.
From: Business Wire
Business Editors/Health/Medical Writers
SAN DIEGO--(BUSINESS WIRE)--May 29, 2003
Women First HealthCare (Nasdaq:WFHC), exclusive distributors of Vaniqa(R)(eflornithine hydrochloride) Cream, 13.9%, today announced the completion of two pilot clinical studies which suggest that Vaniqa(R), in combination with laser hair removal, may improve overall results for women seeking removal of unwanted facial hair.
To date, one U.S. and one Canadian study have been conducted on the safety and efficacy of the combination of laser hair removal treatments and Vaniqa(R) therapy. The ...
About Our Articles: We've partnered with Highbeam Research to provide these article excerpts for your research needs. However, due to copyright laws, we cannot publish the whole article. To view these articles in full length you'll need to use the link above to access the free trial at Highbeam.